Why Zepbound (Tirzepatide) Causes Injection Site Reactions: The Mechanism Explained

What the label reports

In the pooled Zepbound weight-reduction trials (Study 1 and Study 2), injection site reactions were reported in 2% of placebo patients and 6%, 8%, and 8% of patients on 5 mg, 10 mg, and 15 mg once weekly [1]. The label groups bruising, erythema, pruritus, pain, rash, and the term injection site reaction under that heading [1]. It lists injection site reactions among the common adverse reactions occurring in at least 5% of Zepbound-treated patients [1].

Does an antibody response explain it?

One analysis offers a drug-specific association. It pooled 7 phase 3 tirzepatide trials in 5,025 people with type 2 diabetes. Treatment-emergent anti-tirzepatide antibodies developed in 51.1% of treated patients. More antibody-positive patients had hypersensitivity reactions or injection site reactions than antibody-negative patients. The majority of those reactions were nonserious and nonsevere, and most events occurred and/or resolved regardless of antibody status or titer [2]. That analysis was in people with type 2 diabetes, not the Zepbound weight-reduction trials. It reports an association; it does not identify a mechanism for the local reaction.

Local reaction or serious hypersensitivity?

The label lists injection site reactions separately from serious hypersensitivity reactions. In the pooled weight-reduction trials, severe hypersensitivity reactions occurred in 0.1% of Zepbound-treated patients and no placebo patients [1]. Postmarketing reports include anaphylaxis and angioedema [1]. The label says to seek medical attention promptly and discontinue Zepbound if a hypersensitivity reaction is suspected [1]. Zepbound is contraindicated in people with a known serious hypersensitivity to tirzepatide or any excipient in Zepbound [1].

What the label says about the injection itself

Zepbound is a once-weekly subcutaneous injection [1]. The label directs injection into the abdomen, thigh, or back of the upper arm (the upper arm is injected by another person) and says to rotate sites [1]. The label lists vial, prefilled single-dose pen, and single-patient-use KwikPen presentations [1].